Adlai Nortye Ltd. Annual Report - How They Did This Year

I’ve put together this guide to help you understand Adlai Nortye’s performance over the past year. My goal is to explain their financial filings in plain English so you can decide if this company fits your investment goals.

1. What does this company do?

Adlai Nortye is a clinical-stage biopharmaceutical company focused on immuno-oncology. Because they are still in the research phase, they do not have products on the market. Their primary focus is advancing clinical trials for drug candidates like buparlisib (AN2025) and palupiprant (AN0025).

The company is currently transitioning its corporate home base from the Cayman Islands to Singapore. This structural change may impact shareholder rights and governance, so it is a factor to monitor as the move progresses.

2. Financial performance

The company is currently in a "spending phase," prioritizing research over revenue generation.

• Research & Development Costs: Spending decreased from $58.2 million in 2023 to $32.8 million in 2025. This reduction suggests a strategic narrowing of focus toward their most promising late-stage trials, such as the Phase 3 testing for buparlisib.
• Net Loss: The company reported a loss of approximately $48.5 million for 2025, driven by the high costs of global clinical operations without offsetting product sales.

3. Business Model and Strategy

Adlai Nortye utilizes an "out-licensing" model, where they partner with larger pharmaceutical firms to develop and commercialize their discoveries. Their partnership with Novartis for buparlisib is a central component of this strategy. While this model can generate milestone payments, it carries inherent risks; if research goals are not met, the company may lose these payments or the rights to the drugs themselves.

4. Financial Health

The company is currently managing a working capital deficiency. With approximately $15.2 million in cash against over $35 million in immediate liabilities, their current spending exceeds their available cash. Investors should anticipate that the company will likely need to raise additional capital, which could involve issuing more shares and diluting existing ownership.

5. Key Risks

• Clinical Trial Outcomes: The company’s value is tied to the success of its drug candidates in safety and efficacy trials. A failed trial can lead to a significant decline in company value.
• Commercialization and Reimbursement: The company has not yet launched a product. Even if a drug is approved, they face the challenge of building a sales infrastructure or relying on partners, as well as the risk that insurance providers may not offer sufficient coverage for patients.
• Regulatory and Operational Environment: Operating across 18 international markets requires strict adherence to complex regulations. Issues regarding data privacy or the emergence of counterfeit versions of their drugs could result in legal, financial, and reputational damage.

6. Competitive Positioning

Adlai Nortye operates in a highly competitive landscape against major pharmaceutical companies like Merck and AstraZeneca. These competitors possess significantly larger R&D budgets and established infrastructure, which may allow them to bring competing drugs to market faster or more effectively, potentially impacting the relevance of Adlai Nortye’s pipeline.

7. Future Outlook

The company’s path forward is defined by the "regulatory gauntlet"—the process of proving their drugs to authorities like the FDA. Because clinical trials are inherently uncertain and the company requires significant capital to sustain operations over the next 18–24 months, this remains a high-risk, long-term investment.

Decision Checklist:

• Risk Tolerance: Are you comfortable with a company that has no current revenue and a high probability of share dilution?
• Timeline: Are you prepared to wait 24 months or longer to see if their late-stage trials yield results?
• Portfolio Fit: Does this speculative biotech play align with your overall investment strategy, or is it better suited as a small, high-risk portion of your portfolio?